尼洛替尼和达沙替尼作为二三线药物治疗慢性髓性白血病慢性期和加速期患者的疗效及影响因素分析

OBJECTIVE: To explore the efficacy and prognosis of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia (CML) in the chronic phase (CP) and accelerated phase (AP). METHODS: From January 2008 to November 2018, the data of CML patients who failed first-...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2020
Materias:
论著
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357953/
https://www.ncbi.nlm.nih.gov/pubmed/32135623
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.02.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357953/
https://www.ncbi.nlm.nih.gov/pubmed/32135623
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.02.002

Ejemplares similares